Osaic Holdings’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Osaic Holdings’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,564	Closed	-$6.12K	–	7568
2023 Q2	$6.12K	Hold	4,564	–	–	﹤0.01%	6214
2023 Q1	$6.48K	Hold	4,564	–	–	﹤0.01%	6220
2022 Q4	$7K	Buy	4,564 +3,707	+433%	+$10.8K	﹤0.01%	6154
2022 Q3	$4K	Hold	857	–	–	﹤0.01%	6537
2022 Q2	$3K	Sell	857 -28	-3%	-$80	﹤0.01%	6786
2022 Q1	$190K	Sell	885 -2,857	-76%	-$8.61K	﹤0.01%	4076
2021 Q4	$15K	Sell	3,742 -1,257	-25%	-$6.71K	﹤0.01%	6008
2021 Q3	$39K	Buy	+4,999	New	+$49.3K	﹤0.01%	5300
2021 Q2	–	Sell	-540	Closed	-$5K	–	7164
2021 Q1	$5K	Buy	+540	New	+$5.63K	﹤0.01%	6189
2020 Q4	–	Sell	-81	Closed	–	–	6620
2020 Q3	$0	Hold	81	–	–	﹤0.01%	6457
2020 Q2	$1K	Buy	81 +57	+238%	+$859	﹤0.01%	6012
2020 Q1	$0	Buy	+24	New	+$521	﹤0.01%	6217

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Osaic Holdings's VIRX Position: Q3 2023 in Review

Osaic Holdings sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2023, closing a stake of 4,564 shares — an estimated $6.12K sold.

Osaic Holdings first reported a position in VIRX in Q1 2020 and held it in 12 quarters. The position peaked at $190K in Q1 2022. 42 funds tracked by Wall St. Rank hold VIRX as of Q3 2023.

Osaic Holdings reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Osaic Holdings sold 4,564 Viracta Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $6.12K.
Osaic Holdings first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
Osaic Holdings's Viracta Therapeutics, Inc. Common Stock position peaked at $190K in Q1 2022.
42 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Osaic Holdings's 13F filing for Q3 2023, filed 13 Nov 2023.